300357.SZ - Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Shenzhen - Shenzhen Delayed Price. Currency in CNY
Get access to 40+ years of historical data with Yahoo Finance Plus Essential.Learn more
Currency in CNY

Valuation Measures4

Yahoo Finance Plus required to access annual data
Annual
Quarterly
Yahoo Finance Plus required to access monthly data
Monthly
Subscribe to Yahoo Finance Plus Essential to download historical data
 
As of Date: 4/24/2023
Current
12/31/20229/30/20226/30/20223/31/2022
Market Cap (intraday)
22.85B28.85B25.51B27.24B20.32B
Enterprise Value
21.74B27.79B24.46B26.20B19.39B
Trailing P/E
69.7873.8568.6475.8362.72
Forward P/E
N/AN/AN/AN/AN/A
PEG Ratio (5 yr expected)
N/AN/AN/AN/AN/A
Price/Sales (ttm)
25.9332.4830.0632.4126.56
Price/Book (mrq)
11.1514.7314.0814.9012.19
Enterprise Value/Revenue
24.48141.8978.59136.9498.14
Enterprise Value/EBITDA
48.221.36k143.99255.18182.59

Yahoo Finance Plus Essential access required.

Learn more

Trading Information

Stock Price History

Beta (5Y Monthly) 0.44
52-Week Change 3-19.70%
S&P500 52-Week Change 33.90%
52 Week High 358.47
52 Week Low 337.21
50-Day Moving Average 344.99
200-Day Moving Average 349.23

Share Statistics

Avg Vol (3 month) 32.36M
Avg Vol (10 day) 32.81M
Shares Outstanding 5523.58M
Implied Shares Outstanding 6N/A
Float 8214.9M
% Held by Insiders 150.18%
% Held by Institutions 128.63%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 40.2
Forward Annual Dividend Yield 40.54%
Trailing Annual Dividend Rate 30.20
Trailing Annual Dividend Yield 30.53%
5 Year Average Dividend Yield 40.43
Payout Ratio 432.13%
Dividend Date 3N/A
Ex-Dividend Date 4Jun 16, 2022
Last Split Factor 21.8:1
Last Split Date 3May 08, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2022
Most Recent Quarter (mrq)Mar 31, 2023

Profitability

Profit Margin 37.15%
Operating Margin (ttm)34.92%

Management Effectiveness

Return on Assets (ttm)9.10%
Return on Equity (ttm)15.77%

Income Statement

Revenue (ttm)881.57M
Revenue Per Share (ttm)1.68
Quarterly Revenue Growth (yoy)-7.30%
Gross Profit (ttm)854.74M
EBITDA 327.88M
Net Income Avi to Common (ttm)327.52M
Diluted EPS (ttm)0.63
Quarterly Earnings Growth (yoy)-23.20%

Balance Sheet

Total Cash (mrq)1.15B
Total Cash Per Share (mrq)2.2
Total Debt (mrq)39.74M
Total Debt/Equity (mrq)1.90
Current Ratio (mrq)15.59
Book Value Per Share (mrq)3.91

Cash Flow Statement

Operating Cash Flow (ttm)388.6M
Levered Free Cash Flow (ttm)26.68M